

June 1, 2006
AnGes MG, Inc.

Completion of Reexamination of the Basic US Patent on NFκB Decoy Oligonucleotide
-Decision to Maintain Patent-

AnGes MG, Inc. is pleased to announce the completion in the US of the reexamination of NFκB decoy oligonucleotide's basic patent covering treatment for inflammatory diseases, and that a reexamination certificate (US 6,262,033 C1) has recently been published.

Reexamination of this patent had been under way at the US Patent and Trademark Office, following a reexamination request made by an anonymous third party in December 2001. (A "reexamination request" is almost equivalent to an opposition system that was previously in place in Japan.) As a result, the patentability of NFκB decoy oligonucleotide, a drug currently under development at our company, has been reconfirmed, and the decision was made to maintain the said patent.

The reconfirmation of the patentability of this basic patent has shown that the rights to NFκB decoy oligonucleotide which AnGes MG possesses are rock-solid. Moreover, this patent will continue to support our development project.

No other request has been filed, for reexamination, opposition or invalidation trial, in countries other than the US in which the drug's patent has been granted, such as Japan or Europe, and relevant rights are being effectively maintained.

AnGes MG has been filing additional patent applications for the drug's use in other diseases such as atopic dermatitis, asthma, organ transplantation, psoriasis and rheumatoid arthritis. We continue to make efforts to expand the scope of the drug's clinical application.